HBV Antigen‐Guided Switching Strategy From Nucleos(t)ide Analogue to Interferon: Avoid Virologic Breakthrough and Improve Functional Cure
Journal of Medical Virology · 2024
DOI: 10.1002/jmv.70021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Da Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei,…. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Antiviral Agents, DNA, Viral, Interferon-alpha. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: This work was supported by the National Key Research and Development Program of China (2023YFC2308600), National Natural Science Foundation of China (NO.822025….
Abstract (Originalsprache)
Little is known for factors associated with virologic breakthrough (VBT) after switching from nucleos(t)ide analogue (NA) to pegylated interferon alpha (Peg‐IFN‐α) for patients with chronic hepatitis B (CHB). Eighty patients who received 48‐week Peg‐IFN‐ɑ and NA combination therapy followed by Peg‐IFN‐ɑ monotherapy for additional 48 weeks were included in this study. HBV‐related markers including HBV DNA, HBsAg, HBcrAg, HBeAg, cccDNA, and immunological biomarkers were dynamically evaluated. Twelve (15.0%) patients experienced VBT after switching to Peg‐IFN‐ɑ and exhibited significantly lower rates of HBsAg loss after therapy completion (0% vs. 35.3%, p = 0.014). The patients with HBcrAg≥ 5 log 10 U/mL and HBsAg≥ 100 IU/mL had the highest risk of VBT and failed to achieve subsequent HBsAg clearance. Intrahepatic cccDNA level was significantly higher in patients with HBcrAg≥ 5 log 10 U/mL than those with HBcrAg< 5 log 10 U/mL. Notably, in contrast to patients with HBcrAg< 5 log 10 U/mL or with HBsAg< 100 IU/mL who had obviously restored HBV‐specific CD8 + T cell, Tfh or B cell responses before NA cessation, those with HBcrAg≥ 5 log 10 U/mL or with HBsAg≥ 100 IU/mL exhibited lackluster immunities before NA cessation and notable diminished immune responses thereafter. Monitoring HBcrAg and HBsAg levels, which correlated with poor immune responses during sequential Peg‐IFN‐ɑ strategy, may help to avoid VBT and improve functional cure of CHB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
- State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
ORCID-Profile: Qin Ning
Förderung
- This work was supported by the National Key Research and Development Program of China (2023YFC2308600), National Natural Science Foundation of China (NO.822025…
Zitieren
APA
Huang, D., Yuan, Z., Wu, D., Yuan, W., Chang, J., Chen, Y., Ning, Q., & Yan, W. (2024). HBV Antigen‐Guided Switching Strategy From Nucleos(t)ide Analogue to Interferon: Avoid Virologic Breakthrough and Improve Functional Cure. Journal of Medical Virology. https://doi.org/10.1002/jmv.70021
Vancouver
Huang D, Yuan Z, Wu D, Yuan W, Chang J, Chen Y, et al. HBV Antigen‐Guided Switching Strategy From Nucleos(t)ide Analogue to Interferon: Avoid Virologic Breakthrough and Improve Functional Cure. Journal of Medical Virology. 2024. doi:10.1002/jmv.70021
BibTeX
@article{Huang2024,
author = {Huang, Da and Yuan, Zhize and Wu, Di and Yuan, Wei and Chang, Jiang and Chen, Yuying and Ning, Qin and Yan, Weiming},
title = {HBV Antigen‐Guided Switching Strategy From Nucleos(t)ide Analogue to Interferon: Avoid Virologic Breakthrough and Improve Functional Cure},
journal = {Journal of Medical Virology},
year = {2024},
doi = {10.1002/jmv.70021}
}
EUVIMED